Melitracen and flupentixol (deanxit) use disorder in Lebanon

• DOI: 10.1016/j.heliyon.2023.e15847
• Publication Date: 2023-05-02T21:30:55Z
• Authors: Tharwat El Zahran; Sally Al Hassan; Malak Khalifeh; Diana Aboukhater; Lina Hammoud; Moustafa Al Hariri; Ziad Kazzi
• Keywords: Social sciences (General); H1-99; Q1-390; Melitracen; Deanxit; Science (General); Withdrawal; Substance use disorder; Dependence; Flupentixol; 3. Good health; Research Article

IntroductionDeanxit is a combination of melitracen and flupentixol, not approved as an antidepressant for sale use in several countries but still widely available commonly used among the Lebanese population. The study aimed to assess Deanxit disorder, source medication, consumers' awareness therapeutic side effects Deanxit, population.MethodsThis cross-sectional that included all patients taking visited Emergency Department between October 2019 2020. All who agreed participate research through written consent forms were contacted by telephone questionnaire was filled out.ResultsA total 125 study. According DSM-V criteria, 36% (n = 45) had disorder. Most participants females 99, 79.2%), married 90, 72%), ages 40–65 years 71, 56.8%). 41, 91%) prescribed physician anxiety 28, 62%), obtained it using prescription 91%). Almost half 60, 48%) did have sufficient knowledge reason prescribed, 54.4% 68) sure they are medication appropriately, 19.2% 23) satisfied overall explanation physicians concerning use.ConclusionDeanxit disorder underrecognized patients. our their reported inadequate its risk abuse.